Skip to main content
SpringerLink
Log in

Collateral Sensitivity and Cross-Resistance

  • Chapter
Antitumor Drug Resistance

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 72))

Abstract

During the past 10 years cancer chemotherapy has established a valuable role in the management of many human malignancies. Its introduction has significantly improved the prognosis of patients with breast, ovarian and oat-cell lung cancers, and has resulted in long-term survivors or “cures” in cases of testicular teratomas, leukaemias, lymphomas and certain paediatric solid tumours (Carter 1978; Zubrod 1979). However, the overall success rate for many solid tumours remains low. Further progress depends on identifying factors which influence our failures and finding ways of overcoming or circumventing them. Drug resistance, once considered a rather academic enigma, now poses a major practical clinical problem. The high response rates of many tumours to chemotherapy reported in the literature are too often accompanied by very short durations of remission and failure to respond to subsequent therapy. Similarly overgrowth of drug-resistant tumour cells from initially predominantly sensitive populations is commonly seen with a variety of murine solid tumours used as predictive models for drug therapy (Schabel et al. 1980).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahmann F, Meyskens F, Jones S, Durie B, Alberts D, Salmon S (1980) A broad phase-II trial of AMSA with in vitro stem-cell culture drug sensitivity correlations. Proc Am Soc Clin Oncol 21:369

    Google Scholar 

  • Alberts DS, Salmon SE, Chen HSG, Surwit EA, Soehnlein B, Young L (1980 a) In vitro detection of cross-resistance and sensitivity in relapsing ovarian cancer with the human stem-cell assay. Proc Am Assoc Cancer Res 21:181

    Google Scholar 

  • Alberts DS, Salmon SE, Chen HSG, Surwit EA, Soehnlein B, Young L, Moon TE (1980b) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 11:340–342

    Article  Google Scholar 

  • Alexander J, Adamson DJ, Wheeler GP (1980) Effects of two nitrosoureas upon cultured sensitive and resistant LI210 cells. Proc Am Assoc Cancer Res 21:13

    Google Scholar 

  • Ansfield FJ, Callas G, Singson J, Uy B (1980) Further phase I—II studies with oral tegafur (Ftorafur). Proc Am Soc Clin Oncol 21:347

    Google Scholar 

  • Bayssas M, Gouveia J, De Vassal F, Misset JL, Machover D, Schwarzenberg L, Schnieder M, Mathe G (1979) Phase-II clinical trials with vindesine for remission induction in leukemias and lymphomas. Apparent absence of cross resistance with vincristine. Proc Am Assoc Cancer Res 20:48

    Google Scholar 

  • Bech-Hansen NT, Till JE, Ling V (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: Cross-resistance and collateral sensitivity. J Cell Physiol 88:23–32

    Article  PubMed  CAS  Google Scholar 

  • Biedler JL, Riehm H (1970) Cellular resistance to actinomycin-D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Res 30:1174–1184

    PubMed  CAS  Google Scholar 

  • Biedler JL, Meyers MB, Peterson RHF, Spengler BA (1980) Marker chromosome with a homogenously staining region in vincristine-resistant cells. Proc Am Assoc Cancer Res 21:292

    Google Scholar 

  • Biermann WA, Catalano RB, Engstrom PF (1979) A positive phase-II study of dibromo-dulcitol in previously treated patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 20:373

    Google Scholar 

  • Bosmann HB, Kessel D (1970) Altered glycosidase levels in drug-resistant mouse leu-kemias. Mol Pharmacol 6:345–349

    PubMed  CAS  Google Scholar 

  • Brabbs S, Warr JR (1979) Isolation and characterisation of bleomycin-resistant clones of CHO cells. Genet Res 34:269–279

    Article  PubMed  CAS  Google Scholar 

  • Brockman RW (1974) Circumvention of resistance. In: Pharmacological basis of cancer chemotherapy. 27th Annual symposium on fundamental cancer research. Williams and Wilkins, Baltimore, pp 695–711

    Google Scholar 

  • Brockman RW, Yajisawa Y, Ling V, Schabel FM, DiMarco A, Harrap KR, Holland JF (1978) Modes of acquiring resistance to chemotherapeutic agents. In: Siegenthaler W, Luthy (eds) Current chemotherapy. American Society for Microbiology, pp 97–102

    Google Scholar 

  • Browman GP, Lazarus H (1980) Combination antifol therapy: observations on the development of resistant LI 210 leukemic cells in vivo. Cancer Treat Rep 64:231–236

    PubMed  CAS  Google Scholar 

  • Buzdar AU, Legha SS, Hortobagyi GN, Blumenschein GR, Bodey GP (1980) Phase-II evaluation of AMSA in combination with peptichemio in metastatic breast cancer resistant to conventional chemotherapy. Proc Am Assoc Cancer Res 21:181

    Google Scholar 

  • Carter SK (1978) Cancer chemotherapy as it approaches middle age. Cancer Chemother Pharmacol 1:1–4

    PubMed  CAS  Google Scholar 

  • Connors TA (1974) Mechanisms of clinical drug resistance to alkylating agents. Biochem Pharmacol 23 [Suppl 2]:89–100

    Google Scholar 

  • Courtenay VD, Robins AB (1972) Loss of resistance to methotrexate in L5178Y mouse leukemia grown in vitro. J Natl Cancer Inst 49:45–53

    PubMed  CAS  Google Scholar 

  • Creagan ET, Ahmann DL, Ingle JN, Purvis HI JD (1980) Phase II study of 7V-(phosphonoacetyl)-l-asparate (PALA) in disseminated malignant melanoma. Proc Am Soc Clin Oncol 21:344

    Google Scholar 

  • Dano K (1976) Experimentally developed cellular resistance to daunomycin. Acta Pathol Microbiol Scand [A] [Suppl 256]: 1–78

    Google Scholar 

  • Dasgupta I, Steinherz L, Steinherz P, Tan C (1979) Trial of rubidazone in children with cancer. Proc Am Assoc Cancer Res 20:156

    Google Scholar 

  • DeMars R (1974) Resistance of cultured human fibroblasts and other cells to purine and pyrimidine analogs in relation to mutagenesis detection. Mutation Res 24:335–364

    Article  PubMed  CAS  Google Scholar 

  • Devita VT, Serpick A A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895

    PubMed  Google Scholar 

  • Dombernowsky P, Hansen HH (1980) m-AMSA in advanced ovarian carcinoma - a phase-II study. Proc Am Soc Clin Oncol 21:426

    Google Scholar 

  • Douglass HO, Kaufmann J, Engstrom PF, Klaassen DJ, Carbone PP (1979) Single agent chemotherapy of advanced colorectal cancer with ICRF-159, Yoshi-864, piperazinedione, CCNU, actinomycin D, l-PAM or methotrexate. Proc Am Soc Clin Oncol 20:434

    Google Scholar 

  • Fischer GA (1962) Defective transport of amethopterin(methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochem Pharmacol 11:1233–1234

    Article  PubMed  CAS  Google Scholar 

  • Flintoff WF, Davidson SV, Siminovitch L (1976) Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somatic Cell Genet 2:245–261

    Article  PubMed  CAS  Google Scholar 

  • Fox BW (1969) The sensitivity of the Yoshida sarcoma to methylene dimethane sulphon-ate. Int J Cancer 4:54–60

    Article  PubMed  CAS  Google Scholar 

  • Fox BW (1977) Collateral sensitivity between methylene dimethane sulfonate and halogenated methotrexate derivatives in the Yoshida sarcoma in vivo and in vitro. J Natl Cancer Inst 58:955–958

    PubMed  CAS  Google Scholar 

  • Fuks JZ, Van Echo DA, Aisner J, Kravitz S, Wiernik PN (1980) A phase II trial of AMSA in patients with renal cell carcinoma and refractory small cell carcinoma of the lung. Proc Am Soc Clin Oncol 21:477

    Google Scholar 

  • Goldenberg GJ (1975) The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L5178Y lymphoblasts. Cancer Res 35:1687–1692

    PubMed  CAS  Google Scholar 

  • Gorton SJ, Zelkowitz L, Agrawal BL, Stott PB (1980) Treatment of breast cancer patients who have failedCytoxan, methotrexate and 5-fluorouracil with Cytoxan and 5-fluorouracil. Proc Am Soc Clin Oncol 21:347

    Google Scholar 

  • Hakes TB, Wittes JT, Wittes RE, Knapper WH (1979) ay-Platinum diamminedichloro-platinum II in breast cancer: high versus low dose. Proc Am Assoc Clin Oncol 20:304

    Google Scholar 

  • Hakimi J, Bosmann HB (1977) Collateral sensitivity: problems of demonstration in murine leukaemia cells. Biochem Pharmacol 26:1094–1096

    Article  PubMed  CAS  Google Scholar 

  • Hall SW, Benjamin RS, Legha SS, Gutterman JU, Burgess MA, Bodey GP (1979) AMSA: A new acridine derivative with activity against metastatic melanoma. Proc Am Soc Clin Oncol 20:372

    Google Scholar 

  • Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463

    Article  PubMed  CAS  Google Scholar 

  • Harrap KR, Hill BT (1969 a) The selectivity of action of alkylating agents and drug resistance. I. Biochemical changes occurring in sensitive and resistant strains of Yoshida ascites sarcoma following chemotherapy. Br J Cancer 23:210–226

    Article  PubMed  CAS  Google Scholar 

  • Harrap KR, Hill BT (1969 b) The selectivity of action of alkylating agents and drug resistance. II. A comparison of the effects of alkylating drugs on growth inhibition and cell size in sensitive and resistant strains of the Yoshida ascites sarcoma. Br J Cancer 23:227–234

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Canellos GP (1980) Cancer of the breast - the past decade. N Engl J Med 302:78–90

    Article  PubMed  CAS  Google Scholar 

  • Herman TS, Cress AE, Gerner EW (1979) Collateral sensitivity to methotrexate in cells resistant to adriamycin. Cancer Res 39:1937–1942

    PubMed  CAS  Google Scholar 

  • Hill BT, Hellmann K (1977) Razoxane and methotrexate resistance. Lancet 1:47

    Article  PubMed  CAS  Google Scholar 

  • Hill BT, Whelan RDH (1982) Establishment of vincristine-resistant and vindesine-esistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. Cancer Chemother Pharmacol 8:163–169

    Article  PubMed  CAS  Google Scholar 

  • Hill BT, Goldie JH, Price LA (1973) Studies concerned with overcoming resistance to methotrexate: A comparison of the effects of methotrexate and 2,4-diamino-5-(3′,4’-dichlorophenyl)-6-methylpyrimidine on the colony-forming ability of L5178Y cells. Br J Cancer 28:262–268

    Google Scholar 

  • Hill BT, Price LA, Goldie JH (1975) Methotrexate resistance and uptake of DDMP by L5178Y cells - selective protection with folinic acid. Eur J Cancer 11:545–553

    Article  PubMed  CAS  Google Scholar 

  • Hill BT, Price LA, Goldie JH (1976) The value of adriamycin in overcoming resistance to methotrexate in tissue culture. Eur J Cancer 12:541–549

    Article  PubMed  CAS  Google Scholar 

  • Hoshino A, Kato T, Amo H, Ota K (1972) Antitumour effects of adriamycin on Yoshida rat sarcoma and LI210 mouse leukaemia - cross-resistance and combination chemotherapy. In: Carter SK, DiMarco A, Ghione M, Krakoff IH, Mathe E (eds) International symposium on adriamycin. Springer, Berlin Heidelberg New York, pp 75–89

    Google Scholar 

  • Hubbard SM, Barkes P, Young RC (1978) Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62:1375–1377

    PubMed  CAS  Google Scholar 

  • Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP (1980) A phase-II study of peptichemio in advanced breast cancer. Cancer 45:2524–2528

    Article  PubMed  CAS  Google Scholar 

  • Hutchison DJ (1963) Cross resistance and collateral sensitivity studies in cancer chemotherapy. Adv Cancer Res 7:235–350

    Article  PubMed  CAS  Google Scholar 

  • Hutchison DJ (1965) Studies on cross-resistance and collateral sensitivity. Cancer Res 25:1581–1595

    PubMed  CAS  Google Scholar 

  • Hutchison DJ, Schmid FA (1973) Cross resistance and collateral sensitivity. In: Mihich E (ed) Drug resistance and selectivity - biochemical and cellular basis. Academic, New York, pp 73–126

    Google Scholar 

  • Hutchison DJ, Schmid FA (1974) Collateral sensitivity of drug treated and drug-resistant lines of LI 210 leukaemia. Prog Chemother 111:849–853

    Google Scholar 

  • Inaba M, Johnson RK (1977) Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukaemia. Cancer Res 37:4629–4634

    PubMed  CAS  Google Scholar 

  • Ingle JN, Ahmann DL, Bisel HF, Rubin J, Kvols LK (1979) Randomized phase-II trial of rubidazone and adriamycin in women with advanced breast cancer. Proc Am Assoc Clin Oncol 20:427

    Google Scholar 

  • Jayaram HN, Cooney DA, Vistica DT, Kariya S, Johnson RK (1979) Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA). Cancer Treat Rep 63:1291–1302

    PubMed  CAS  Google Scholar 

  • Johnson RK, Chitnis MP, Embrey WM, Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535–1547

    PubMed  CAS  Google Scholar 

  • Kaufman RJ, Brown PC, Schimke RT (1979) Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 76:5669–5673

    Article  PubMed  CAS  Google Scholar 

  • Kaye SB, Boden J A (1980) Cross-resistance between actinomycin D, adriamycin and vincristine in a murine solid tumour in vivo. Biochem Pharmacol 29:1081–1084

    Article  PubMed  CAS  Google Scholar 

  • Kline I, Woodman RJ, Gang M, Venditti JM (1971) Effectiveness of anti-leukaemic agents in mice inoculated with leukaemia LI210 variants resistant to 5-(3,3-dimethyl-l-triazeno) imidazole-4-carboxamide or 5-[3,3-bis(2-chloroethyl)-l-triazeno]imidazole-4-carboxamide. Cancer Chemother Rep 55:9–28

    PubMed  CAS  Google Scholar 

  • Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1974) A controlled study of combined l,3-bis-(2-chloroethyl)-l-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563–567

    Article  PubMed  CAS  Google Scholar 

  • Laster WR, Schabel FM (1979) Collateral sensitivity of P388/Ara-C and P388/5-FU to N-(phosphonacetyl)-L-aspartate (PALA). Proc Am Assoc Cancer Res 20:95

    Google Scholar 

  • Lawrence HJ, Ries CA, Reynolds RD, Lewis JP, Koretz MM (1980) m-AMSA: a promising new agent in refractory acute leukemia. Proc Am Soc Clin Oncol 21:438

    Google Scholar 

  • Leichman L, Buroker TR, O’Bryan RM, Baker LH (1980) A phase-II trial of AMSA in disseminated adenocarcinoma of the colon and rectum. Proc Am Soc Clin Oncol 21:355

    Google Scholar 

  • Ling V (1975) Drug resistance and membrane alteration in mutants of mammalian cells. Can J Genet Cytol 17:503–515

    PubMed  CAS  Google Scholar 

  • Livingston RB (1980) Small-cell carcinoma of the lung. Blood 56:575–584

    PubMed  CAS  Google Scholar 

  • Magill GB, Sordillo P, Gralla R, Golbey RB (1980) Phase-II trials of DVA, AMSA and DCNU as single agents in adult sarcomas. Proc Am Soc Clin Oncol 21:362

    Google Scholar 

  • Mihich E (1973) Tumor immunogenicity in therapeutics. In: Mihich E (ed) Drug resistance and selectivity, biochemical and cellular basis. Academic, New York, pp 391–412

    Google Scholar 

  • Mihich E, Kitano M (1971) Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res 31:1999–2003

    PubMed  CAS  Google Scholar 

  • Ohnoshi T, Ohnuma T, Holland JF (1980) Establishment of methotrexate-resistant human acute lymphocytic leukemia cells in culture and effects of various antifols. Proc Am Assoc Cancer Res 21:298

    Google Scholar 

  • Orkin SH, Littlefield JW (1971) Mutagenesis to aminopterin resistance in cultured hamster cells. Exp Cell Res 69:174–180

    Article  PubMed  CAS  Google Scholar 

  • Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109–4112

    PubMed  CAS  Google Scholar 

  • Reich SD, Bradner WT (1979) Responses of mitomycin-C-resistant lines of L1210 leukemia to treatment with chemotherapeutic drugs. Proc Am Assoc Cancer Res 20:214

    Google Scholar 

  • Reynolds TF, Cvitkovic E, Golbey RB, Young CW (1979) Phase-II trial of vindesine in patients with germ cell tumors. Proc Am Soc Clin Oncol 20:338

    Google Scholar 

  • Riehm H, Biedler JL (1971) Cellular resistance to daunomycin in Chinese hamster cells in vitro. Cancer Res 31:409–412

    PubMed  CAS  Google Scholar 

  • Rosen G, Nirenberg A, Juergens H, Tan C (1970) Phase-II trial of cw-platinum in oesteo-genic sarcoma. Proc Am Soc Clin Oncol 20:363

    Google Scholar 

  • Rosenfelt FP, Sikic BI, Daniels JR, Rosenbloom BE (1980) Phase II evaluation of cis- diamminedichloroplatinum in small cell carcinoma of lung. Proc Am Soc Clin Oncol 21:449

    Google Scholar 

  • Rossof AH, Chandra G, Wolter J, Showel J (1979) Phase II trial of vindesine in advanced metastatic cancer. Proc Am Assoc Cancer Res 20:146

    Google Scholar 

  • Rozencweig M, Von Hoff DD, Muggia FM (1978) New agents - selected problems in drug development and clinical testing. In Brodsky I, Kahn S, Conroy JF (eds) Cancer chemotherapy III. The 46th Hahneman Symposium. Grune and Stratton, New York, pp 75–85

    Google Scholar 

  • Rutman RJ (1964) Experimental chemotherapy studies. V. The collateral sensitivity to alkylating agents of several antimetabolite-resistant ascites tumors in mice. Cancer Res 24:634–638

    PubMed  CAS  Google Scholar 

  • Salmon SE, Hamburger AW, Soehnlein B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327

    Article  PubMed  CAS  Google Scholar 

  • Samal BA, McDonald B, Kim PM, McKenzie M, Baker L (1980) m-AMSA for treatment of disseminated breast cancer. Proc Am Soc Clin Oncol 21:363

    Google Scholar 

  • Schabel FM (1979) Test systems for evaluating the antitumor activity of nucleoside analogs. In: Walker RT, De Clercq E, Eckstein F (eds) Nucleoside analogues. Plenum, New York, pp 363–394

    Google Scholar 

  • Schabel FM, Trader MW, Laster WR, Wheeler GP, Witt MH (1978) Patterns of resistance and therapeutic synergism among alkylating agents. In: Schabel FM (ed) Fundamentals in cancer chemotherapy, antibiotics and chemotherapy, vol 23. Karger, Basel, pp 200–215

    Google Scholar 

  • Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP (1979) c/s-Dichlorodiam-mineplatinum II. Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473

    PubMed  CAS  Google Scholar 

  • Schabel FM, Skipper HE, Trader MW, Laster WR, Corbett TH, Griswold DP (1980) Concepts for controlling drug-resistant tumour cells. In: Mouridsen HT, Palshof T (eds) Breast cancer: Experimental and clinical aspects. Pergamon, Oxford, pp 199–212

    Google Scholar 

  • Schmid FA, Hutchison DJ (1971) Induction and characteristics of resistance to L-aspara-ginase (NSC-109229) in mouse leukemia L5178Y. Cancer Chemother Rep 55:115–121

    PubMed  CAS  Google Scholar 

  • Schmid FA, Stock CC (1976) Antitumor activity of peptichemio. Proc Am Assoc Cancer Res 17:49

    Google Scholar 

  • Siegfried JM, Kennedy KA, Tritton TR (1980) Investigation of adriamycin-resistant cell lines with respect to proposed mechanisms of drug action. Proc Am Assoc Cancer Res 21:12

    Google Scholar 

  • Siminovitch L (1976) On the nature of hereditable variation in cultured somatic cells. Cell 7:1–11

    Article  PubMed  CAS  Google Scholar 

  • Skelley M, Tormey D, Robins HI, Falkson G, Crowley J, Falkson H, Ansfield F (1980) Phase-II trial of vindesine in advanced breast cancer patients. Proc Am Assoc Cancer Res 21:172

    Google Scholar 

  • Skipper HE, Hutchison DJ, Schabel FM, Schmidt LH, Goldin A, Brockman RW, Venditti JM, Wodinsky I (1972) A quick reference chart on cross-resistance between anticancer agents. Cancer Chemother Rep 56:493–498

    PubMed  CAS  Google Scholar 

  • Skipper HE, Schabel FM, Lloyd HH (1978) Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumour cells. Semin Haematol 15:207–219

    CAS  Google Scholar 

  • Skipper HE, Schabel FM, Lloyd HH (1979) Dose-response and tumor-cell repopulation rate in chemotherapeutic trials. In: Rosowsky A (ed) Advances in cancer chemotherapy, vol 1. Marcel Dekker, New York, pp 205–253

    Google Scholar 

  • Slay ton R, Creasman W, Bundy B (1979 a) Phase-II trial of VP-16 in treatment of advanced squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 20:365

    Google Scholar 

  • Slay ton R, Petty W, Blessing J (1979 b) Phase-II trial of VP-16 in treatment of advanced ovarian adenocarcinoma. Proc Am Assoc Cancer Res 20:190

    Google Scholar 

  • Stambaugh JE (1980) Vindesine in the treatment of patients with advanced neoplastic disease. Proc Am Soc Clin Oncol 21:344

    Google Scholar 

  • Sugimura T (1970) In: Nakahara W (ed) Chemical tumour problems. Jap Soc for the Promotion of Sci, Tokyo, pp 269–284

    Google Scholar 

  • Szybalski W, Bryson V (1952) Genetic studies on microbial cross-resistance to toxic agents I. Cross-resistance of Escherichia coli to fifteen antibiotics. J Bacteriol 64:489–499

    PubMed  CAS  Google Scholar 

  • Thigpen T, Lagasse L, Bundy B (1979) Phase-II trial of ds-platinum in treatment of advanced ovarian adenocarcinoma. Proc Am Assoc Cancer Res 20:84

    Google Scholar 

  • Thompson LH, Baker RM (1973) Isolation of mutants of cultured mammalian cells. In: Prescott DM (ed) Methods in cell biology, vol 6 Academic, London, pp 209–281

    Google Scholar 

  • Tiber C, Conrad F, Hagemeister R (1980) Continuous vinblastine for previously treated non-Hodgkin’s lymphoma. Proc Am Assoc Cancer Res 21:162

    Google Scholar 

  • Tsukagoshi S, Hashimoto Y (1973) Increased immunosensitivity in nitrogen mustard-resistant Yoshida sarcoma. Cancer Res 33:1038–1042

    PubMed  CAS  Google Scholar 

  • Van Echo DA, Aisner J, Wirnik PH (1979) Combination chemotherapy of advanced breast cancer with adriamycin and VP16–213. Proc. Am Assoc Cancer Res 20:228

    Google Scholar 

  • Volm M, Lindner C (1978) Detection of induced resistance in short term tests. Adriamy-cin-resistant sarcoma 180. Z Krebsforsch 91:1–10

    Article  CAS  Google Scholar 

  • Von Hoff DD, Casper J, Bradley E, Trent JM, Hodach A, Reichert C, Makuch R, Altman A (1980) Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Res 40:3591–3597

    Google Scholar 

  • Wendt A J, Jones SE, Salmon SE (1980) Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy. Cancer Treat Rep 64:269–273

    PubMed  CAS  Google Scholar 

  • White K (1979) Studies on the mechanism of cellular resistance to the antitumour agent ICRF-159. PhD Thesis, London University

    Google Scholar 

  • Wilkoff LJ, Dulmadge EA (1978 a) Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs and actinomycin-D. J Natl Cancer Inst 61:1521–1524

    PubMed  CAS  Google Scholar 

  • Wilkoff LJ, Dulmadge EA (1978 b) Sensitivity and resistance of cultured leukemia P388 cells to vincristine and 4’-demethyl podophyllotoxin. Proc Am Assoc Cancer Res 19:37

    Google Scholar 

  • Williams SD, Einhorn LH, Greco A, Oldham R, Fletcher R, Bond WH (1979) VP-16–213: an active drug in germinal neoplasms. Proc Am Assoc Cancer Res 20:72

    Google Scholar 

  • Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW (1979) cw-Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61:359–366

    Google Scholar 

  • Wodinsky I, Kensler CJ (1964) Activity of selected compounds in subline of leukaemia LI210 resistant to cytosine arabinoside. Cancer Chemother Rep 43:1–3

    PubMed  CAS  Google Scholar 

  • Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, Distefano A (1980 a) Continuous 5-day infusion vindesine - improvement in therapeutic index in the treatment of refractory breast cancer. Proc Am Soc Clin Oncol 21:408

    Google Scholar 

  • Yap HY, Blumenschein GR, Keating MJ, Horotbagyi GN, Tashima CK, Loo TL (1980 b) Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64:279–283

    PubMed  CAS  Google Scholar 

  • Zubrod CG (1979) Historic milestones in curative chemotherapy. Semin Oncol 6:490–505

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Paterson Laboratories, Christie Hospital and Holt Radium Institute, Wilmslow Road, M20 9BX, Withington, Manchester, UK

    Brian W. Fox Ph. D.  & Margaret Fox  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hill, B.T. (1984). Collateral Sensitivity and Cross-Resistance. In: Fox, B.W., Fox, M. (eds) Antitumor Drug Resistance. Handbook of Experimental Pharmacology, vol 72. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69490-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-69490-5_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-69492-9

  • Online ISBN: 978-3-642-69490-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation